OncoMatch/Clinical Trials/NCT05580601
Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed & Refractory Acute Myeloid Leukemia (AML)
Is NCT05580601 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies CIML-NK Cells for acute myeloid leukemia.
Treatment: CIML-NK Cells — The objective of this study is to demonstrate that cytokine-induced memory-like natural killer cells can be generated from donor cells and infused safely into patients with relapsed or refractory acute myeloid leukemia (AML). A secondary objective is to assess efficacy of the CIML-NK cells in treating AML.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Myeloid Leukemia
Disease stage
Required: Stage RELAPSED, REFRACTORY
Excluded: Stage ISOLATED CENTRAL NERVOUS SYSTEM (CNS) DISEASE, ISOLATED EXTRAMEDULLARY DISEASE
With relapsed or refractory AML in their bone marrow; Disease: isolated central nervous system (CNS) disease, or isolated extramedullary disease, or diagnosis of acute promyelocytic leukemia (APML) [excluded].
Demographics
Lab requirements
Liver function
total bilirubin > 2mg/dl, ast and alt more than three times the upper limit of normal [excluded]
Cardiac function
systolic ejection fraction <45% by echocardiogram [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Cincinnati Children's Hospital Medical Center · Cincinnati, Ohio
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05580601 currently recruiting?
Yes, this trial is currently recruiting patients.
What disease stage is eligible?
Stage RELAPSED or REFRACTORY is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages